List of Excipients in Branded Drug FORTEO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	FORTEO	teriparatide	0002-8400	ACETIC ACID
Eli Lilly and Company	FORTEO	teriparatide	0002-8400	HYDROCHLORIC ACID
Eli Lilly and Company	FORTEO	teriparatide	0002-8400	MANNITOL

FORTEO Excipient Strategy and Commercial Opportunities

Last updated: September 3, 2026

FORTEO is a teriparatide injection supplied in a multidose prefilled delivery device. Its formulation uses a simple acidic aqueous system with mannitol and metacresol. The principal commercial opportunities are preservative-free delivery, improved room-temperature stability, lower-cost multidose devices, differentiated adherence packaging, and follow-on teriparatide products that avoid device and formulation claims. The core molecule has limited long-term exclusivity protection, so formulation and device execution are more important than active-ingredient exclusivity.

What excipients are used in FORTEO?

FORTEO contains teriparatide in an acidic aqueous formulation with four principal inactive ingredients: glacial acetic acid, sodium acetate, mannitol, and metacresol. Water for injection is the vehicle. The formulation has a pH of approximately 4.0. Each cartridge contains 600 micrograms of teriparatide in 2.4 mL of solution, equivalent to 250 micrograms/mL. The marketed dose is 20 micrograms administered subcutaneously once daily.[1]

Component	Function in FORTEO	Commercial relevance
Glacial acetic acid	Acidification and pH adjustment	Controls peptide stability and solubility
Sodium acetate	Acetate buffering	Helps maintain formulation pH
Mannitol	Tonicity agent and stabilizer	Supports injection tolerability and peptide stability
Metacresol	Antimicrobial preservative	Enables multidose cartridge use
Water for injection	Aqueous vehicle	Standard parenteral solvent

The excipient system is conventional for a multidose peptide injection. Its commercial value comes from compatibility with the pen presentation, rather than from a novel excipient combination.

How does the FORTEO formulation work?

The formulation balances four requirements: peptide solubility, chemical stability, microbial control, and injection tolerability.

Acidic pH and acetate buffer

Teriparatide is a 34-amino-acid peptide and is vulnerable to aggregation, oxidation, deamidation, and adsorption under unfavorable storage conditions. The acetate system maintains an acidic environment designed to support chemical stability. A competing product can use a different buffer or pH, but that change requires comparative stability, aggregation, potency, and immunogenicity data.

Mannitol

Mannitol provides tonicity and may reduce some destabilizing effects associated with peptide handling. It also helps create an injection solution with acceptable osmolality. Mannitol is widely used in parenteral products, so it is unlikely to provide meaningful standalone exclusivity.

Metacresol

Metacresol is the key excipient from a product-design perspective. It is the preservative that supports repeated withdrawals from a multidose cartridge. Its use creates potential tolerability, sensitization, and compatibility considerations, particularly for patients requiring long treatment courses.

Replacing metacresol could produce a differentiated product, but the replacement must demonstrate antimicrobial effectiveness, container-closure compatibility, extractables and leachables control, and peptide stability over the full in-use period.

What formulation patents protect FORTEO?

The active ingredient and delivery presentation should be analyzed separately.

Teriparatide itself has limited remaining exclusivity value in the United States. The main competitive barriers are more likely to arise from:

• Pen and cartridge design
• Container-closure systems
• Formulation pH and buffer selection
• Preservative concentration and preservative alternatives
• In-use stability
• Manufacturing controls for peptide purity and aggregation
• Labeling and method-of-use claims

An ANDA applicant can generally use the same or similar inactive ingredients if the proposed product meets FDA requirements and does not infringe enforceable claims. A different excipient system can reduce formulation patent risk, but it can increase regulatory development cost.

The relevant freedom-to-operate review should cover:

1. U.S. patents listed in the FDA Orange Book for FORTEO and any authorized generics.
2. Continuations and divisionals covering teriparatide formulations.
3. Device patents covering the prefilled pen, dose-delivery mechanism, cartridge, and dose counter.
4. Manufacturing patents covering peptide folding, purification, oxidation control, and impurity removal.
5. Foreign patents in Europe, Japan, Canada, Australia, and high-volume emerging markets.

The Orange Book should be reviewed at the time of filing because listed patents and regulatory status can change.[2]

When does FORTEO lose exclusivity?

FORTEO no longer has the commercial profile of a molecule protected by active-ingredient exclusivity. FDA approval occurred in 2002, and the original five-year new-chemical-entity exclusivity period has expired. Pediatric exclusivity and later patent rights also do not prevent broad follow-on competition indefinitely.[1,3]

Exclusivity element	FORTEO position
FDA approval	2002
New chemical entity exclusivity	Expired
Biologic exclusivity	Not applicable
Biosimilar pathway	Not applicable
Generic or follow-on pathway	Available, subject to FDA requirements
Key residual barriers	Formulation, device, manufacturing, patents, and market access

Teriparatide is regulated as a drug, not as a biologic requiring a biosimilar application under section 351(k). Follow-on products can pursue an ANDA where the reference-product requirements are satisfied, or a 505(b)(2) application where the product differs materially in formulation, presentation, or clinical use.[4]

What FDA regulatory status applies to teriparatide generics?

Teriparatide follow-on products are generally evaluated through drug pathways rather than biosimilar pathways. An ANDA strategy is most attractive when the applicant can match the reference product’s dosage form, route, strength, formulation characteristics, and delivery system.

A 505(b)(2) strategy is more suitable for products such as:

• Preservative-free teriparatide
• A single-dose cartridge or disposable injector
• A lyophilized teriparatide product requiring reconstitution
• A formulation with extended refrigerated or room-temperature stability
• A new delivery device
• A product with a modified dosing schedule supported by clinical evidence

A formulation change from metacresol to another preservative, or to a preservative-free system, would likely require more than routine pharmaceutical-equivalence work. The sponsor would need to establish microbiological control and demonstrate that the new excipients do not alter peptide quality, potency, delivery, or safety.

What excipient strategies could create commercial differentiation?

1. Preservative-free teriparatide

The strongest formulation opportunity is a preservative-free presentation. A single-dose pen, unit-dose syringe, or sealed cartridge could remove the need for metacresol.

Advantages include:

• Lower exposure to preservative-related irritation or sensitivity
• Better positioning for long-term treatment
• Potential use in patients who do not tolerate metacresol
• Clear product differentiation from standard multidose presentations

The main disadvantage is higher packaging cost. A single-dose format also creates more injection components and may generate greater medical waste.

2. Alternative antimicrobial systems

A multidose product could investigate alternative preservatives or antimicrobial container technologies. This route is technically difficult because preservatives can interact with peptides, elastomers, adhesives, and device components.

Potential development issues include:

• Preservative adsorption to the cartridge
• Peptide oxidation or aggregation
• Changes in delivered dose
• Preservative loss during storage
• Local injection-site tolerability
• Antimicrobial effectiveness during repeated use

A new preservative system may support formulation patent claims if the composition and stability profile are sufficiently distinctive.

3. Improved room-temperature stability

The approved FORTEO labeling requires refrigerated storage at 2°C to 8°C and instructs patients to discard the delivery device after the applicable in-use period.[1] A formulation that remains stable during short-term temperature excursions could reduce supply-chain losses and improve patient convenience.

Potential approaches include:

• Alternative buffer systems
• Peptide stabilizers
• Optimized pH
• Reduced oxygen exposure
• Improved cartridge materials
• Lyophilization
• Integrated temperature-control packaging

Room-temperature stability is commercially valuable in markets with weak cold-chain infrastructure. The development burden includes long-term, accelerated, photostability, agitation, freeze-thaw, and in-use studies.

4. Lyophilized teriparatide

A lyophilized product could improve storage stability and reduce degradation during distribution. It would require reconstitution immediately before use or a dual-chamber delivery system.

This strategy may support premium pricing in markets where refrigerated distribution is expensive. It also introduces drawbacks:

• More complex administration
• Reconstitution errors
• Greater device cost
• Potential loss of adherence
• Additional particulate and reconstitution testing

The best commercial application would likely be a dual-chamber pen that automatically mixes the diluent and peptide.

5. Device-compatible excipient optimization

FORTEO’s commercial design depends on a multidose pen. Excipients must remain compatible with:

• Cartridge glass
• Elastomeric stoppers
• Needle assemblies
• Lubricants
• Dose-metering components
• Adhesives and coatings

A competing product could use the same active ingredient and similar excipients but obtain commercial differentiation through a lower-cost pen, a smaller device, a clearer dose indicator, or a cartridge with a longer in-use period.

Which companies are challenging FORTEO?

Teriparatide competition has emerged from generic and follow-on manufacturers rather than biosimilar developers. FDA-approved competitors have included products from manufacturers such as Alvogen and Teva, subject to product-specific approval and marketing status.[5]

Competitive review should distinguish among:

• Approved ANDA products
• 505(b)(2) products
• Authorized generics
• Products approved but not actively marketed
• Foreign teriparatide products
• Combination products using teriparatide or related anabolic agents

The principal competitive advantage for a generic manufacturer is lower cost. The principal advantage for a differentiated 505(b)(2) sponsor is a superior presentation, stability profile, or patient experience.

What generic entry risks exist for FORTEO?

Price erosion

Teriparatide has a high risk of price erosion once multiple products are available. The largest impact falls on the reference product’s retail and payer reimbursement, while differentiated products may preserve pricing through device convenience or specialty-pharmacy positioning.

Device substitution

A device that is not substitutable for the reference pen can reduce automatic pharmacy substitution. This may give the manufacturer more control over pricing but can increase prescriber education and payer contracting requirements.

Formulation workarounds

A generic applicant can avoid a formulation patent by changing buffer composition, preservative concentration, cartridge materials, or device configuration. The reference sponsor must therefore protect the entire product architecture rather than relying only on the core excipient list.

Manufacturing barriers

Teriparatide manufacturing requires control of peptide purity, aggregates, oxidation products, truncated sequences, residual process impurities, and delivered-dose uniformity. These requirements create technical barriers, but they are not absolute barriers for established peptide manufacturers.

How strong is the FORTEO patent estate?

The FORTEO estate is weaker against conventional generic entry than a newer branded peptide product because the original active-ingredient exclusivity has expired. Its strongest remaining protection, where enforceable claims remain, is likely to be concentrated in:

• Device configurations
• Cartridge systems
• Specific formulation ranges
• In-use stability
• Manufacturing processes
• Method-of-use claims

Method-of-use patents may have limited commercial effect if generic labels omit protected indications or dosing instructions. Device patents may be more important if the reference product’s commercial value depends on a proprietary pen.

Patent strength should be scored claim by claim. Broad claims covering any teriparatide formulation are more vulnerable than narrow claims limited to specific pH ranges, preservative concentrations, stability periods, or device structures.

What licensing opportunities exist around FORTEO excipients?

Licensing opportunities are more likely to involve enabling technologies than the basic FORTEO excipient list. Relevant assets include:

• Preservative-free multidose delivery
• Low-adsorption cartridge coatings
• Peptide stabilization platforms
• Dual-chamber injection systems
• Room-temperature storage technologies
• Microneedle or wearable delivery
• Manufacturing processes that reduce aggregates
• Packaging systems that limit oxygen and moisture ingress

A licensee should avoid paying for broad excipient claims that can be designed around easily. The strongest deal candidates are technologies that combine formulation claims with device, stability, and manufacturing know-how.

What is the commercial opportunity for a next-generation teriparatide product?

The most credible commercial opportunity is a differentiated follow-on product with one or more of the following attributes:

Product concept	Regulatory route	Commercial rationale
Low-cost generic pen	ANDA	Broad payer access and price competition
Preservative-free single-dose pen	505(b)(2) or relevant hybrid route	Tolerability and patient differentiation
Longer in-use period	505(b)(2)	Reduced waste and improved convenience
Room-temperature-stable product	505(b)(2)	Lower cold-chain cost
Dual-chamber lyophilized pen	505(b)(2)	Stability and logistics benefits
Smaller or simpler injector	ANDA or 505(b)(2)	Lower device cost and improved usability
International multidose presentation	Local pathway	Access in price-sensitive markets

The commercial ceiling is constrained by the availability of low-cost generic teriparatide and competing anabolic osteoporosis treatments, including abaloparatide and romosozumab. A new product must show a measurable advantage in cost, convenience, tolerability, storage, or payer economics.

Key Takeaways

• FORTEO uses an acidic acetate-buffered aqueous formulation containing mannitol and metacresol.
• Metacresol is the most commercially relevant excipient because it enables multidose use.
• Teriparatide is not subject to a biosimilar pathway; generic and 505(b)(2) strategies are more relevant.
• The strongest product opportunities are preservative-free delivery, improved temperature stability, and lower-cost pen systems.
• Formulation, device, manufacturing, and in-use stability claims are more important than expired active-ingredient exclusivity.
• Generic entry creates substantial price pressure, while differentiated presentations may support specialty-market pricing.
• A successful licensing strategy should target integrated formulation-device technologies rather than commodity excipients.

FAQs

Can a generic FORTEO use the same metacresol formulation?

Yes. A generic may use the same inactive ingredients if it satisfies FDA requirements and does not infringe enforceable patent claims. The applicant must still demonstrate pharmaceutical quality, stability, container compatibility, and product performance.

Is metacresol necessary for a teriparatide pen?

Metacresol is necessary for a multidose system that relies on preservative-based microbial control, but it is not inherently necessary for all teriparatide products. A unit-dose or aseptic single-use presentation could eliminate the preservative.

Could teriparatide be reformulated for room-temperature storage?

Potentially. The formulation would require comprehensive stability and in-use data. Peptide aggregation, oxidation, adsorption, and potency loss are the principal technical risks.

Does a preservative-free teriparatide product require clinical trials?

The requirement depends on the formulation and regulatory pathway. A sufficiently comparable product may rely on analytical and clinical bridging data, while a materially different formulation or delivery system may require additional clinical evidence under a 505(b)(2) application.

Is FORTEO exposed to biosimilar competition?

No. Teriparatide is regulated as a drug rather than a biologic for purposes of the U.S. biosimilar pathway. Its principal competition comes from generic and follow-on teriparatide products.

References

1. Eli Lilly and Company. (2023). FORTEO (teriparatide injection) prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Drug approval package: FORTEO (teriparatide). U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). 505(b)(2) applications. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Drugs@FDA: Teriparatide injection products. U.S. Department of Health and Human Services.